Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

Found 1097 recommendations for 557 medicines and 34 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
  1. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 60 mg tablet (dispersible, scored) (as sulfate); 300 mg tablet (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  2. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  3. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  4. Acetazolamide General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
    Indications
    Primary open-angle glaucoma
  5. Acetic acid General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% in alcohol
    Indications
    Infectious diseases of external ear
  6. Acetylcysteine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
    Indications
    Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  7. Acetylsalicylic acid General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Indications
    Acute myocardial infarction Cerebral ischaemic stroke
    Section
    Juvenile joint diseases
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
    Pain
  8. Aciclovir General information
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Indications
    Zoster Varicella Herpes simplex infections
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
    Indications
    Herpes simplex keratitis
  9. Activated charcoal General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Other: powder
    Indications
    Unspecified injury, poisoning or certain other consequences of external causes
  10. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Juvenile idiopathic arthritis Rheumatoid arthritis
  11. Albendazole General information
    Section
    Antifilarials
    • Oral > Solid: 400 mg tablet (chewable)
    Indications
    Filariasis
    Section
    Intestinal anthelminthics
    • Oral > Solid: 400 mg tablet (chewable)
    Indications
    Echinococcosis Ascariasis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis
  12. Alcohol based hand rub General information
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
    Indications
    Denatured alcohol
  13. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  14. Allopurinol General information
    Section
    Supportive medicines
    • Oral > Solid: 100 mg tablet; 300 mg tablet
    Indications
    Tumour lysis syndrome
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Gout
  15. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
    Indications
    Cerebral ischaemic stroke
  16. Amidotrizoate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
    Amidotrizoate
  17. Amikacin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)
    Second choice
    co-prescribed with cloxacillin Sepsis without septic shock
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection (as sulfate); 500 mg in vial powder for injection (as sulfate); 100 mg in vial powder for injection (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  18. Amiloride General information
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
    Indications
    Oedema Ascites
  19. Amiodarone General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Cardiac arrhythmia
  20. Amitriptyline General information
    Section
    Medicines used in depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Indications
    Depressive disorders
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 25 mg; 10 mg; 75 mg
    Indications
    Palliative care
  21. Amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
    Indications
    Essential hypertension
  22. Amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  23. Amodiaquine + sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
    Malaria
  24. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    Indications
    First choice
    Periapical abscess without sinus Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute otitis media Acute sinusitis Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Infectious cystitis co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
  25. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    First choice
    Neutropenia (low-risk) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Other specified pneumonia (Hospital-acquired pneumonia) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Chronic obstructive pulmonary disease with acute exacerbation
    Second choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Other specified prophylactic measures Acute otitis media Bacterial infection of joint Osteomyelitis or osteitis co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
    Section
    Antituberculosis medicines
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  26. Amphotericin b General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
    Indications
    Candidosis Blastomycosis Aspergillosis Cryptococcosis Coccidioidomycosis Histoplasmosis Sporotrichosis
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
    Indications
    Visceral leishmaniasis
  27. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
  28. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  29. Anti-d immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Maternal care for red cell antibodies Rh incompatibility reaction
  30. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  31. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  32. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  33. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
    Indications
    Nausea or vomiting
  34. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  35. Artemether General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection)
    Indications
    Malaria due to Plasmodium falciparum
  36. Artemether + lumefantrine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
    Indications
    Malaria due to Plasmodium falciparum
  37. Artesunate General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
    • Oral > Solid: 50 mg tablet
    • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
    Indications
    Malaria due to Plasmodium falciparum
  38. Artesunate + amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
    Indications
    Malaria due to Plasmodium falciparum
  39. Artesunate + mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
    Indications
    Malaria due to Plasmodium falciparum
  40. Artesunate + pyronaridine tetraphosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
    Indications
    Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
  41. Ascorbic acid General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Scurvy
  42. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  43. Atazanavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  44. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  45. Atenolol General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  46. Atorvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  47. Atracurium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
    Muscle relaxants
  48. Atropine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Indications
    Exposure to or harmful effects of undetermined intent of pesticides
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Anterior uveitis
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Indications
    Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics
  49. Azathioprine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 50 mg
    Indications
    Rheumatoid arthritis, serology unspecified Psoriatic arthritis
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
    • Oral > Solid: 50 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  50. Azithromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Trachoma
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
    Indications
    First choice
    Typhoid fever Cholera Paratyphoid fever Chlamydia trachomatis co-prescribed with ceftriaxone Gonococcal infection
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection
    Other indications
    Trachoma Yaws
  51. Barium sulfate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
    Barium sulfate with suspending agents
  52. Bcg vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  53. Beclometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
    Indications
    Asthma
  54. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  55. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  56. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
    Indications
    First choice
    Syphilis Congenital syphilis [children]
  57. Benznidazole General information
    Section
    American trypanosomiasis
    • Oral > Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet
    Indications
    Chagas disease
  58. Benzoyl peroxide General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
    Acne
  59. Benzyl benzoate General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
    Indications
    Pthiriasis Pediculosis corporis Pediculosis capitis Scabies
  60. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    First choice
    Congenital syphilis [children] Syphilis co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
  61. Betamethasone General information
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
    Indications
    Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus
  62. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
  63. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  64. Biperiden General information
    Section
    Antiparkinsonism medicines
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
    Indications
    Parkinson disease
  65. Bisoprolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Angina pectoris
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Heart failure
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Cardiac arrhythmia
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Essential hypertension
  66. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Hodgkin lymphoma Kaposi sarcoma of unspecified primary site
  67. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  68. Budesonide General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 100 µg per dose
    Indications
    Allergic rhinitis
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
    Indications
    Asthma
  69. Budesonide + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
    Indications
    Asthma
  70. Bupivacaine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
    Indications
    Local anaesthetics
  71. Buprenorphine General information
    Section
    Medicines for disorders due to psychoactive substance use
    Indications
    Therapeutic equivalent to methadone for Opioid dependence
  72. Caffeine citrate General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    Indications
    Apnoea of newborn
  73. Calamine General information
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
    Pruritus
  74. Calcium General information
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
    Indications
    Calcium deficiency
  76. Calcium gluconate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Hypermagnesaemia
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Tetany due to acute calcium deficiency
  78. Carbamazepine General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable)
    Indications
    Epilepsy or seizures
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 100 mg scored; 200 mg scored
    Indications
    Bipolar or related disorders
  79. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
    Indications
    Postpartum haemorrhage
  80. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  82. Carvedilol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  83. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
    Indications
    Second choice
    Acute pharyngitis Bacterial cellulitis, erysipelas or lymphangitis Chronic obstructive pulmonary disease with acute exacerbation
  84. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
  85. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection
  86. Cefotaxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Other specified pneumonia (Hospital-acquired pneumonia) co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate)
    Second choice
    Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Osteomyelitis or osteitis
  87. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    Pseudomonas aeruginosa resistant to other antibiotic
  88. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  89. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Bacterial meningitis Other specified pneumonia (Hospital-acquired pneumonia) Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate)
    Second choice
    Acute pyelonephritis (mild to moderate) Inflammatory and other diseases of prostate (mild to moderate) Osteomyelitis or osteitis Bacterial infection of joint Sepsis without septic shock Infectious gastroenteritis or colitis without specification of infectious agent
  90. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  91. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  92. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  93. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Second choice
    Bacterial meningitis
  94. Chlorhexidine General information
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Indications
    Omphalitis of newborn
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
    Chlorhexidine
  95. Chlorine base compound General information
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    Indications
    Disinfectant, not elsewhere classified
  96. Chloroquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium vivax
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium malariae Malaria due to Plasmodium vivax
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
    Indications
    Rheumatoid arthritis
  97. Chloroxylenol General information
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
    Indications
    Phenol disinfectant, not elsewhere classified
  98. Chlorpromazine General information
    Section
    Medicines used in psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Schizophrenia or other primary psychotic disorders
  99. Cholera vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  100. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Solid: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  101. Ciprofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Indications
    Infectious diseases of external ear
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
    Indications
    First choice
    Paratyphoid fever Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Acute pyelonephritis (mild to moderate) Neutropenia (low-risk) Infectious gastroenteritis or colitis without specification of infectious agent
    Second choice
    Cholera co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate)
  103. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 500 mg
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    Indications
    First choice
    co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choice
    Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Other indications
    Helicobacter pylori associated gastric ulcer
  104. Clindamycin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    Indications
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
  105. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Leprosy
  106. Clomifene General information
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
    Indications
    Female infertility without specification whether primary or secondary
  107. Clomipramine General information
    Section
    Medicines used for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Obsessive-compulsive disorder
  108. Clopidogrel General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
    Indications
    Acute ischaemic heart disease Presence of coronary angioplasty implant or graft
  109. Clotrimazole General information
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
    Indications
    Vulvovaginal candidosis
  110. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
    Indications
    First choice
    Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial infection of joint
    Second choice
    co-prescribed with amikacin Sepsis without septic shock
  111. Clozapine General information
    Section
    Medicines used in psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  112. Coagulation factor ix complex General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  113. Coagulation factor viii General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
    Indications
    Haemophilia A
  114. Coal tar General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Psoriasis of unspecified type
  115. Codeine General information
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Pain
  116. Colecalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
    Indications
    Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Calcium deficiency Therapeutic equivalent to ergocalciferol for Vitamin D deficiency
  117. Colistin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  118. Compound sodium lactate solution General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock
  120. Copper-containing intrauterine device General information
    Section
    Intrauterine devices
    • -
    Indications
    Contact with health services for insertion of contraceptive device
  121. Cyclizine General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 50 mg tablet
    • Parenteral > General injections > unspecified: 50 mg per mL
    Indications
    Palliative care
  123. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  124. Cytarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Myeloid leukaemia
  125. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  126. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  127. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
    Indications
    Chronic hepatitis C
  128. Dactinomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 µg in vial powder for injection
    Indications
    Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  129. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Venous thromboembolism Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease
  130. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  131. Darbepoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  132. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  133. Dasabuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
    Indications
    Chronic hepatitis C
  134. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  135. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia
  136. Deferoxamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Harmful effects of drugs, medicaments or biological substances, not elsewhere classified
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
  137. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  138. Dengue vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  139. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 10 µg per dose (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  140. Dexamethasone General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Indications
    Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Indications
    Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Palliative care
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Allergic or hypersensitivity conditions of unspecified type
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
    • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Nausea or vomiting
  141. Dextran 70 General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
    Hypovolaemia
  143. Diazepam General information
    Section
    Anticonvulsants/antiepileptics
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
    • Local > Rectal > Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
    Indications
    Status epilepticus
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Anxiety
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 5 mg; 10 mg
    • Local > Rectal > Solution: 2.5 mg; 5 mg; 10 mg
    • Parenteral > General injections > unspecified: 5 mg per mL
    Indications
    Palliative care
  144. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  145. Diethylcarbamazine General information
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
    Indications
    Lymphatic filariasis
  146. Digoxin General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Cardiac arrhythmia
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
    Heart failure
  147. Dihydroartemisinin + piperaquine phosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
    Indications
    Malaria due to Plasmodium falciparum
  148. Diloxanide General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
    Amoebiasis
  149. Dimercaprol General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  150. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  151. Diphtheria vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  152. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate
  153. Docusate sodium General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg capsule
    Indications
    Palliative care
  154. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  155. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  156. Dopamine General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
    Indications
    Cardiogenic shock Heart failure
  158. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid: 100 mg (as hyclate)
    Indications
    First choice
    Chlamydia trachomatis Cholera
    Second choice
    Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
    Indications
    Malaria due to Plasmodium falciparum
  159. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet; 200 mg scored tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  160. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  161. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  162. Eflornithine General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 100 mL bottle (hydrochloride)
    Indications
    African trypanosomiasis
  163. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
  164. Enalapril General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
    Indications
    Heart failure
  165. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    Indications
    Venous thromboembolism Acute ischaemic heart disease
  166. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  167. Ephedrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
    Cardiac complications of anaesthesia during labour or delivery
  168. Epinephrine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Cardiac arrest
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Indications
    Primary open-angle glaucoma
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Asthma Chronic obstructive pulmonary disease
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
    Anaphylaxis
  169. Epoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  170. Epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  171. Epoetin theta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  172. Ergocalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
    Indications
    Calcium deficiency Vitamin D deficiency
  173. Ergometrine General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
    Indications
    Postpartum haemorrhage
  174. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  175. Erythromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Indications
    First choice
    Chlamydial conjunctivitis Gonococcal infection of eye
  176. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  177. Estradiol cypionate + medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
    Indications
    Contact with health services for reasons associated with reproduction
  178. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  179. Ethambutol General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 25 mg per mL
    • Oral > Solid: 100 to 400 mg tablet (hydrochloride); 100 mg dispersible tablet
    Indications
    Tuberculosis
  180. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  181. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  182. Ethanol General information
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
    Indications
    Denatured alcohol
  183. Ethinylestradiol + levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 µg + 150 µg
    Indications
    Contact with health services for contraceptive management
  184. Ethinylestradiol + norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
    Indications
    Contact with health services for contraceptive management
  185. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 125 mg tablet; 250 mg tablet; 125 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  186. Ethosuximide General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
    Indications
    Absence seizures, typical
  187. Etonogestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
    Indications
    Contact with health services for insertion of contraceptive device
  189. Fentanyl General information
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
    Indications
    Chronic cancer pain
  190. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL iron (as sulfate)
    • Oral > Solid: 60 mg iron
    Indications
    Iron deficiency anaemia
  191. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 400 µg tablet
    Indications
    Maternal care for other specified conditions predominantly related to pregnancy
  192. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Indications
    African trypanosomiasis
  193. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  194. Fluconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 50 mg capsule
    Indications
    Cryptococcosis Candidosis
  195. Flucytosine General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
    Cryptococcosis
  196. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  197. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  198. Fluorescein General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
    Fluorescein
  199. Fluoride General information
    Section
    Vitamins and minerals
    • In any appropriate topical formulation
    Indications
    Dental caries
  200. Fluorouracil General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
    Indications
    Malignant neoplasms of breast Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum Malignant neoplasms of colon
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
    Plantar warts
  201. Fluoxetine General information
    Section
    Medicines used in depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Depressive disorders
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Palliative care
  202. Fluphenazine General information
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
    Schizophrenia or other primary psychotic disorders
  203. Fluvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  204. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    • Oral > Solid: 400 µg
    Indications
    Folate deficiency anaemia Cephalocele Anencephaly or similar anomalies Spina bifida
  205. Fomepizole General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  206. Fosfomycin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  207. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  208. Furosemide General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL
    • Oral > Solid: 40 mg; 10 mg; 20 mg
    Indications
    Oedema Anuria or oliguria
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL
    • Oral > Solid: 40 mg
    Indications
    Heart failure
  209. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  210. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Sepsis without septic shock co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shock
    Second choice
    Other specified prophylactic measures Gonococcal infection
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
    Indications
    Other specified conjunctivitis Infectious blepharitis
  211. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet
    Indications
    Chronic hepatitis C
  212. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  213. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
    Indications
    Hypoglycaemia in the context of diabetes
  214. Glucose General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance Hypoglycaemia without associated diabetes
  215. Glucose + sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  216. Glutaral General information
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
    Indications
    Glutaral nonmedicinal
  217. Glyceryl trinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
    Angina pectoris
  218. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  219. Griseofulvin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
    Dermatophytosis
  220. Haemophilus influenzae type b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  221. Haloperidol General information
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 2 mg; 0.5 mg; 5 mg
    Indications
    Schizophrenia or other primary psychotic disorders
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Palliative care
  222. Halothane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  223. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  224. Hepatitis a vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  225. Hepatitis b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  226. Hpv vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  227. Hydralazine General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
    Indications
    Gestational hypertension
  228. Hydrochlorothiazide General information
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Solid: 25 mg
    Indications
    Oedema
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Indications
    Essential hypertension
  229. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Adrenocortical insufficiency
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema:
    Indications
    Ulcerative colitis Crohn disease site
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Anaphylaxis
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
    Indications
    Pruritus due to skin disorder Psoriasis of unspecified type Dermatitis or eczema Lichen planus
  230. Hydromorphone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  231. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  232. Hydroxycarbamide General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid: 200 mg; 500 mg; 1 g
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  233. Hydroxychloroquine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
    Indications
    Systemic lupus erythematosus
  234. Hyoscine butylbromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
    Palliative care
  235. Hyoscine hydrobromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
    Palliative care
  236. Ibuprofen General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Migraine
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Indications
    Patent arterial duct
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Pain
  237. Ifosfamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Osteosarcoma of bone and articular cartilage of unspecified sites
  239. Indometacin General information
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen for Patent arterial duct
  240. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  241. Influenza vaccine (seasonal) General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  242. Insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble)
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  243. Intermediate-acting insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  244. Intraperitoneal dialysis solution General information
    Section
    Peritoneal dialysis solution
    • parenteral solution
    Indications
    Care involving peritoneal dialysis
  245. Iodine General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
    • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
    • Oral > Solid: 190 mg
    Indications
    Iodine deficiency
  246. Iohexol General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
    X-ray contrast media, iodinated
  247. Ipratropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 20 µg per dose
    Indications
    Asthma Chronic obstructive pulmonary disease
  248. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine
  249. Isoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  250. Isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 100 to 300 mg tablet; 50 mg tablet (scored); 100 mg tablet (dispersible)
    Indications
    Tuberculosis
  251. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible); 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  252. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
    Indications
    Other specified prophylactic measures
  253. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
    Tuberculosis
  254. Isosorbide dinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
    Angina pectoris
  256. Ivermectin General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 3 mg tablet (scored)
    Indications
    Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
    Section
    Antifilarials
    • Oral > Solid: 3 mg tablet (scored)
    Indications
    Onchocerciasis Lymphatic filariasis
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid: 3 mg tablet (scored)
    Indications
    Scabies
  257. Japanese encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  258. Ketamine General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
    Indications
    Anaesthetics and therapeutic gases
  259. Lactulose General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
    Indications
    Palliative care
  260. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  261. Lamivudine + nevirapine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  262. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  263. Lamotrigine General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
    Indications
    Other specified epilepsy or seizures
  264. Latanoprost General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
    Indications
    Primary open-angle glaucoma
  265. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  266. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  267. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  268. Levamisole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 50 mg tablet; 150 mg tablet (as hydrochloride)
    Indications
    Ascariasis
  269. Levodopa + carbidopa General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
    Indications
    Parkinson disease
  270. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  271. Levonorgestrel General information
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Indications
    Contact with health services for insertion of contraceptive device
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Indications
    Contact with health services for postcoital contraception Contact with health services for contraceptive management
  272. Levonorgestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
    Indications
    Contact with health services for insertion of contraceptive device
  273. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  274. Lidocaine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Indications
    Ventricular tachyarrhythmia
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
    Local anaesthetics
  275. Lidocaine + epinephrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
    Local anaesthetics
  276. Linezolid General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet; 150 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    Indications
    Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
  277. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
    Indications
    Essential hypertension
  278. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
    Indications
    Essential hypertension
  279. Lithium carbonate General information
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 300 mg
    Indications
    Bipolar or related disorders
  280. Loperamide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 2 mg solid oral dosage form
    Indications
    Palliative care
  281. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Liquid: 400 mg + 100 mg per 5 mL
    • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  282. Loratadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL oral liquid
    • Oral > Solid: 10 mg tablet
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  283. Lorazepam General information
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Indications
    Status epilepticus
  284. Losartan General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Essential hypertension
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
    Heart failure
  285. Lovastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  286. Lugol's solution General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
    Thyrotoxicosis
  287. Magnesium sulfate General information
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
    Indications
    Severe pre-eclampsia Eclampsia
  288. Mannitol General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
    Indications
    Ocular hypertension Cerebral oedema
  289. Measles vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  290. Mebendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
  291. Medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Indications
    Contact with health services for reasons associated with reproduction
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  292. Mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  293. Meglumine antimoniate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  294. Meglumine iotroxate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
    X-ray contrast media, iodinated
  295. Melarsoprol General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
    Indications
    African trypanosomiasis
  296. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  297. Meningococcal meningitis vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  299. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Peritoneal abscess (severe) Neonatal meningitis Neutropenia (high-risk) Peritonitis (severe)
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  300. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii
  301. Mesalazine General information
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine for Ulcerative colitis Therapeutic equivalent to sulfasalazine for Crohn disease site
  303. Metformin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  304. Methadone General information
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (as hydrochloride); 10 mg per 5 mL (as hydrochloride); 5 mg per mL concentrate for oral liquid (as hydrochloride); 10 mg per mL concentrate for oral liquid (as hydrochloride)
    • Oral > Solid: 5 mg (as hydrochloride); 10 mg (as hydrochloride)
    Indications
    Chronic cancer pain
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Indications
    Opioid dependence
  305. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Thyrotoxicosis
  306. Methotrexate General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
    • Oral > Solid: 2.5 mg (as sodium salt)
    Indications
    Malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 2.5 mg (as sodium salt)
    Indications
    Rheumatoid arthritis, serology unspecified
  307. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  308. Methyldopa General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
    Indications
    Gestational hypertension
  309. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified
  310. Methylthioninium chloride General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
    Indications
    Acquired methaemoglobinaemia
  311. Metoclopramide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Nausea or vomiting
  312. Metoprolol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  313. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    Indications
    First choice
    Trichomoniasis Intestinal infections due to Clostridioides difficile co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe)
    Second choice
    co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate)
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    Indications
    Amoebiasis
  314. Miconazole General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
    Indications
    Fungal infection of the skin
  315. Midazolam General information
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 15 mg tablet; 7.5 mg tablet
    Indications
    Sedative-hypnotic and anxiolytic drugs
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (for buccal administration); 10 mg per mL in ampoule (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL solution for oromucosal administration; 10 mg per mL solution for oromucosal administration
    Indications
    Status epilepticus
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL oral liquid
    • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
    • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
    Indications
    Palliative care
  316. Mifepristone - misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
    Termination of pregnancy, affecting surviving fetus or newborn
  317. Miltefosine General information
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  318. Misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 µg
    • Local > Vaginal > tablet: 25 µg
    Indications
    Unspecified abortion, incomplete, without complication Complications of labour or delivery Postpartum haemorrhage
  319. Morphine General information
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
    Indications
    Opioids or related analgesics and agents affecting opioid receptors
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
    • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
    • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Pain
  320. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  321. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Oral > Other:
    Indications
    Iron deficiency anaemia
  322. Mumps vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  323. Mupirocin General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
    Indications
    Superficial bacterial folliculitis Impetigo
  324. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Venous thromboembolism Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease
  325. Naloxone General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
    Indications
    Unintentional exposure to or harmful effects of opioids or related analgesics
  326. Natamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
    Indications
    Infectious keratitis
  327. Neostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Oral > Solid: 15 mg (neostigmine bromide)
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
    Indications
    Myasthenia gravis Anticholinesterase reversible
  328. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL oral solution
    • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  329. Niclosamide General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
    Indications
    Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium
  330. Nicotinamide General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
    Pellagra
  331. Nicotine replacement therapy General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Other: 2 mg chewing gum; 4 mg chewing gum
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
    Indications
    Nicotine dependence
  332. Nifedipine General information
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Indications
    Preterm labour without delivery
  333. Nifurtimox General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 120 mg
    Indications
    African trypanosomiasis
    Section
    American trypanosomiasis
    • Oral > Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet
    Indications
    Chagas disease
  334. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  335. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg tablet
    Indications
    First choice
    Infectious cystitis
  336. Nitrous oxide General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
    Indications
    Anaesthetics and therapeutic gases
  337. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Melanoma of skin
  338. Norethisterone General information
    Section
    Progestogens
    Indications
    Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle
  339. Norethisterone enantate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
    Indications
    Contact with health services for reasons associated with reproduction
  340. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Mucocutaneous lymph node syndrome
  341. Nystatin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL; 50 mg per 5 mL
    • Oral > Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet
    • Local > Topical > Other: 100000 IU pessary
    Indications
    Candidosis
  342. Ofloxacin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
    Indications
    Infectious keratitis
  343. Ombitasvir + paritaprevir + ritonavir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  344. Omeprazole General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
    • Oral > Solid: 10 mg; 20 mg; 40 mg
    • Parenteral > General injections > IV: 40 mg in vial
    Indications
    Gastro-oesophageal reflux disease Peptic ulcer, site unspecified Gastrointestinal bleeding
  345. Ondansetron General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
    Indications
    Palliative care
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
    Indications
    Nausea or vomiting
  346. Oral rehydration salts General information
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Diarrhoea
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  347. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
    Diarrhoea
  348. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Liquid: 12 mg per mL powder for oral liquid
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
    Indications
    Influenza due to identified seasonal influenza virus
  349. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  350. Oxamniquine General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg capsule
    Indications
    Schistosomiasis due to Schistosoma mansoni
  351. Oxycodone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  352. Oxygen General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Indications
    Anaesthetics and therapeutic gases
    Section
    Medical gases
    • Respiratory > Inhalation:
    Indications
    Respiratory failure as acute or chronic
  353. Oxytocin General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
    Indications
    Postpartum haemorrhage
  354. P-aminosalicylic acid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 500 mg tablet; 4 g granules in sachet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  356. Pancreatic enzymes General information
    Section
    Pancreatic enzymes
    • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
    Indications
    Enzyme intestinal
  357. Paracetamol General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
    • Oral > Solid: 300 to 500 mg
    Indications
    Migraine
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 100 mg
    Indications
    Pain
  358. Paromomycin General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Indications
    Visceral leishmaniasis
  359. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial
    Indications
    Lymphoid leukaemia, not elsewhere classified
  360. Pegylated interferon alfa (2a) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  361. Pegylated interferon alfa (2b) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  362. Penicillamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  363. Pentamidine General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 200 mg (as isetionate) powder for injection
    Indications
    African trypanosomiasis
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 200 mg tablet; 300 mg tablet
    Indications
    Pneumocystosis
  364. Permethrin General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
    Indications
    Pediculosis corporis Pediculosis capitis Scabies
  365. Pertussis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  366. Phenobarbital General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid: 15 to 100 mg
    • Parenteral > General injections > IV: 200 mg per mL in ampoule (phenobarbital sodium)
    Indications
    Epilepsy or seizures Status epilepticus
  367. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt)
    Indications
    First choice
    Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute pharyngitis
  368. Phenytoin General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 25 to 30 mg per 5 mL
    • Oral > Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet
    • Parenteral > General injections > unspecified: 50 mg per mL in 5 vial (sodium salt)
    Indications
    Epilepsy or seizures
  369. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
    • Oral > Solid: 10 mg tablet
    Indications
    Haemorrhagic disorder due to other specified circulating anticoagulants Haemorrhagic or haematological disorders of fetus or newborn
  370. Pilocarpine General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
    Indications
    Primary open-angle glaucoma Acute angle closure with pupillary block Ocular hypertension
  371. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    Peritoneal abscess (severe) Neutropenia (high-risk) Peritonitis (severe) Other specified pneumonia (Hospital-acquired pneumonia)
  372. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  373. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  374. Pneumococcal vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  375. Podophyllotoxin General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin for Plantar warts Therapeutic equivalent to podophyllum resin for Anogenital warts
  376. Podophyllum resin General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
    Indications
    Plantar warts Anogenital warts
  377. Poliomyelitis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  378. Polygeline General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    Indications
    Therapeutic equivalent to dextran 70 for Hypovolaemia
  379. Polymyxin b General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 500000 IU in vial powder for injection
    Indications
    Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa
  380. Potassium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Hypokalaemia
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Hypokalaemia
  381. Potassium ferric hexacyanoferrate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  382. Potassium iodide General information
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Sporotrichosis
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 60 mg
    Indications
    Thyrotoxicosis
  383. Potassium permanganate General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
    Indications
    Other specified pyogenic bacterial infection of skin and subcutaneous tissue Tropical phagedaenic ulcer Pemphigus Impetigo
  384. Povidone iodine General information
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
    Povidone iodine
  385. Pravastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  386. Praziquantel General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 600 mg tablet; 150 mg tablet
    • Oral > Solid: 600 mg tablet
    Indications
    Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Hymenolepiasis Diphyllobothriasis
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid: 600 mg tablet
    Indications
    Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
  387. Prednisolone General information
    Section
    Hormones and antihormones
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Plasma cell myeloma Malignant neoplasms of prostate
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Indications
    Scleritis Anterior uveitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Indications
    Allergic or hypersensitivity conditions of unspecified type
  388. Primaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
    Indications
    Malaria due to Plasmodium ovale Malaria due to Plasmodium vivax
  389. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    First choice
    Congenital syphilis [children]
    Second choice
    Syphilis
  390. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  391. Progesterone vaginal ring General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
    Indications
    Contact with health services for contraceptive management
  392. Proguanil General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
    Indications
    Malaria due to Plasmodium falciparum
  393. Propofol General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 10 mg per mL; 20 mg per mL
    Indications
    Anaesthetics and therapeutic gases
  394. Propranolol General information
    Section
    Antimigraine medicines > For prophylaxis
    • Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
    Indications
    Migraine
  395. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  396. Prostaglandin e1 General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
    Indications
    Other specified congenital anomaly of great arteries including arterial duct Therapeutic equivalent to prostaglandin e2 for Other specified congenital anomaly of great arteries including arterial duct
  397. Prostaglandin e2 General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
    Indications
    Therapeutic equivalent to prostaglandin e1 for Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct
  398. Protamine sulfate General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
    Indications
    Haemorrhagic disorder due to other specified circulating anticoagulants
  399. Pyrantel General information
    Section
    Intestinal anthelminthics
    • Oral > Liquid: 50 mg per mL (as embonate or pamoate)
    • Oral > Solid: 250 mg chewable tablet (as embonate or pamoate)
    Indications
    Ascariasis Enterobiasis Trichuriasis Hookworm diseases
  400. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 30 mg per mL
    • Oral > Solid: 400 mg tablet; 150 mg tablet (dispersible); 150 mg tablet (scored)
    Indications
    Tuberculosis
  401. Pyridostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
    • Oral > Solid: 60 mg (pyridostigmine bromide)
    Indications
    Myasthenia gravis
  402. Pyridoxine General information
    Section
    Vitamins and minerals
    • Oral > Solid: 25 mg (hydrochloride)
    Indications
    Vitamin B6 deficiency Sideroblastic anaemia Other specified polyneuropathy
  403. Pyrimethamine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
    Toxoplasmosis
  404. Quinine General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
    • Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
    Indications
    Malaria due to Plasmodium falciparum
  405. Rabies vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  406. Raltegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable); 100 mg tablet (chewable)
    • Oral > Other: 100 mg granules for oral suspension
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  407. Ranitidine General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
    Indications
    Peptic ulcer, site unspecified Gastro-oesophageal reflux disease
  408. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  409. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  410. Retinol General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
    • Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
    • Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
    Indications
    Vitamin A deficiency
  411. Ribavirin General information
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Viral haemorrhagic fever, not elsewhere classified
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  412. Riboflavin General information
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
    Indications
    Vitamin B2 deficiency
  413. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  414. Rifampicin General information
    Section
    Antileprosy medicines
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Tuberculosis
  415. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg tablet
    Indications
    Latent tuberculosis
  416. Risperidone General information
    Section
    Medicines used in psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
    Indications
    Schizophrenia or other primary psychotic disorders
  417. Ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Liquid: 400 mg per 5 mL
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    • Oral > Other: 100 mg powder
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  418. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas
  419. Rotavirus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  420. Rubella vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  421. Salbutamol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
    • Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
    Indications
    Asthma Chronic obstructive pulmonary disease
  422. Salicylic acid General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
    Indications
    Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses
  423. Selenium sulfide General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
    Indications
    Seborrhoeic dermatitis Pityriasis versicolor
  424. Senna General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Palliative care
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
    Constipation
  425. Silver sulfadiazine General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
    Burns
  426. Simvastatin General information
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
    Indications
    Mixed hyperlipidaemia Coronary atherosclerosis
  427. Sodium calcium edetate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  428. Sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
    Indications
    Other specified disorders of fluid, electrolyte or acid-base balance
  429. Sodium hydrogen carbonate General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
    Acidosis
  430. Sodium nitrite General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  431. Sodium nitroprusside General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
    Indications
    Hypertensive crisis
  432. Sodium stibogluconate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
    Indications
    Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis
  433. Sodium thiosulfate General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Solution: 15%
    Indications
    Pityriasis versicolor
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  434. Sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg tablet
    Indications
    Chronic hepatitis C
  435. Sofosbuvir + velpatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg + 100 mg tablet
    Indications
    Chronic hepatitis C
  436. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Gonococcal infection
  437. Spironolactone General information
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Heart failure
    Section
    Diuretics
    • Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Oedema Ascites
  438. Streptokinase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
    Indications
    Acute myocardial infarction
  439. Streptomycin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  440. Succimer General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  441. Sulfadiazine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
    Toxoplasmosis
  442. Sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Indications
    Malaria due to Plasmodium falciparum
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid: 250 mg + 12.5 mg tablet
    Indications
    Malaria due to Plasmodium falciparum Malaria
  443. Sulfamethoxazole + trimethoprim General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    Indications
    Pneumocystosis
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    Indications
    First choice
    Infectious cystitis
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent
  444. Sulfasalazine General information
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema:
    Indications
    Ulcerative colitis Crohn disease site
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Indications
    Rheumatoid arthritis, serology unspecified
  445. Suramin sodium General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
    Indications
    African trypanosomiasis
  446. Surfactant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  447. Suxamethonium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial
    Indications
    Muscle relaxants
  448. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  449. Telmisartan + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
    Indications
    Essential hypertension
  450. Telmisartan + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
    Indications
    Essential hypertension
  451. Tenofovir disoproxil fumarate General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B
  452. Terbinafine General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
    Indications
    Fungal infection of the skin
  453. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  454. Tetanus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  455. Tetracaine General information
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
    Local anaesthetics
  456. Tetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
    Indications
    Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Infectious blepharitis Trachoma
  457. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  458. Thiamine General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg (hydrochloride)
    Indications
    Vitamin B1 deficiency
  459. Tick-borne encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  460. Timolol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
    Indications
    Primary open-angle glaucoma Ocular hypertension
  461. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  462. Tiotropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 18 µg capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
    Indications
    Chronic obstructive pulmonary disease
  463. Tranexamic acid General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Postpartum haemorrhage
  464. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  465. Triclabendazole General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid: 250 mg tablet
    Indications
    Paragonimiasis Fascioliasis
  466. Tropicamide General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
    Cycloplegic drug
  467. Tuberculin, purified protein derivative General information
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
    Indications
    Mycobacterial diseases
  468. Typhoid vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  469. Ulipristal General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
    Indications
    Contact with health services for postcoital contraception
  470. Urea General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
    Indications
    Xerosis cutis or asteatosis
  471. Valaciclovir General information
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella
  472. Valganciclovir General information
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL powder for oral solution
    • Oral > Solid: 450 mg Tablet
    Indications
    Cytomegaloviral retinitis
  473. Valproic acid General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 200 mg per 5 mL (sodium valproate)
    • Oral > Solid: 200 mg (sodium valproate) enteric-coated tablet; 500 mg (sodium valproate) enteric-coated tablet; 100 mg (sodium valproate) crushable tablet
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule (sodium valproate); 100 mg per mL in 10 mL ampoule (sodium valproate)
    Indications
    Epilepsy or seizures Status epilepticus
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 200 mg enteric-coated (sodium valproate); 500 mg enteric-coated (sodium valproate)
    Indications
    Bipolar or related disorders
  474. Vancomycin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Neutropenia (high-risk) Intestinal infections due to Clostridioides difficile
  475. Varicella vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  476. Vecuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
    Muscle relaxants
  477. Verapamil General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Supraventricular tachyarrhythmia
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
    Angina pectoris
  478. Vinblastine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
    Indications
    Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis Kaposi sarcoma of unspecified primary site
  480. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast
  481. Voriconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
    Indications
    Chronic pulmonary aspergillosis Invasive aspergillosis
  482. Warfarin General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)
    Indications
    Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation
  483. Water for injection General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
    Indications
    Unspecified appropriateness of dosing or administration without injury or harm
  484. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  485. Xylometazoline General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL
    Indications
    Nasal congestion
  486. Yellow fever vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  487. Zidovudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 250 mg capsule; 300 mg tablet
    Indications
    Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
  488. Zinc sulfate General information
    Section
    Medicines for diarrhoea
    • Oral > Solid: 20 mg
    Indications
    Diarrhoea
  489. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow